Skip to main content

Table 3 P50 suppression amplitudes of S1, S2, and S1/S2 and latencies at different time points

From: Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot study

 TD (n = 31)TSC (n = 7)
Time pointD0D0D91D119
TrialMean amplitude (SD)Mean amplitude (SD)
S1 amplitude1.65 (1.01)1.42 (.68)1.98 (1.26)1.67 (1.38)
S1 latency61.35 (10.39)62.67 (11.40)63.33 (9.06)62.67 (9.95)
S2 amplitude1.00 (1.04).88 (.70)1.02 (.89).74 (.52)
S2 latency59.27 (15.45)65 (9.97)67.75 (14.44)66.22 (14.12)
S1/S2 ratio.58 (.55).73 (.50).81 (.85).65 (.52)
  1. Abbreviations: TD typically developing controls, TSC tuberous sclerosis complex